For a patient with TP53+ CLL who has been receiving first line ibrutinib for over 7 years with a complete hematologic response but detectable minimal residual disease, would you consider switching now to a novel BTKi such as acalabrutinib or zanubrutinib given better PFS data?   

Patient with unfavorable risk CLL, TP53 mutant, receiving 1L Ibrutinib for 7+ years with excellent hematological response, but detectable MRD, is there any role to switch to the novel BTKi agents given better PFS?

In a patient who has been receiving 1L Ibrutinib for CLL, TP53 mutant who has excellent disease control for 7 years, hematological remission, but detectable MRD, is there any role to switch to novel BTKi such as acalabrutinib or zanubrutinib?